SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community anticipates the launch of a new ETF, sparking discussions about potential institutional investment and increased exposure for HBAR. Community members are actively debating price targets and potential 'sell the news' scenarios, while highlighting Hedera's real-world adoption and strong network growth. Some investors express concerns about past performance and token unlocks.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending ahead of its Q3 earnings report, with investors anticipating strong double-digit growth and debating whether positive results are already priced in. The community is actively discussing potential price movements, including a possible post-earnings sell-off, as well as the potential for SoFi to be added to the S&P 500. Bullish sentiment remains strong among long-term holders, who see a bright future for the fintech company.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the company's L- and S-band frequencies are now part of the official global 3GPP standard, potentially enabling direct-to-device satellite connectivity on billions of existing phones; the community is discussing the significance of this standardization and its impact on scalability and partnerships with mobile network operators. Bullish sentiment surrounds the implications of this milestone, with some speculating about future partnerships and government contracts, while bears express concerns about dilution and valuation.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

TPST is trending amid ongoing speculation of a potential acquisition, with community members highlighting its promising oncology assets and Roche's potential interest. Discussions revolve around Roche's existing collaboration with Tempest and the strategic value of acquiring TPST's liver cancer therapy. Some traders express concerns about cash runway and timing, while others point to technical indicators and potential buyout scenarios, anticipating news soon.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its acquisition of Arduino, a move seen as expanding its reach in AI and robotics. The community is discussing the potential benefits of this acquisition and how it may position the company against competitors. Some traders are closely watching technical indicators and option flow for potential upside.

Project Nema is a research initiative enhancing AI memory and companionship by integrating the C. elegans neural connectome with a large language model (LLM). The LLM translates human language to interact with the worm's simulated brain, addressing LLMs' lack of persistent emotional or psychological states beyond context windows. This creates a stable, evolving neural state that retains history across sessions. For example, user inputs like "good morning Nema" fetch state and history for processing. Utilities include companionship, where Nema acts as the LLM's "soul" for long-term personality building, and dynamic adaptation mimicking life. It also aims to boost LLM outputs via extended memory. The project involves user management and visualizations.

NEMA LAB

NEMA is trending as Project Nema launches its AI-driven digital organism, simulating a worm brain that users can interact with and train. Community members are excited about the project's novel approach, comparing it to an AI Tamagotchi and noting the team's background in brain science. Some are drawing parallels to its predecessor, $WORM, anticipating significant growth potential due to the added utility.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending as analysts discuss its bullish momentum and potential for further gains, particularly noting the strong buying opportunity around the "Blue Box" area. Community discussions revolve around Elliott Wave analysis, identifying key support levels and potential paths for continued upside. Broader market commentary suggests a positive outlook for European equities, with some analysts pointing to potential outperformance compared to U.S. markets.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica ($CLS) is trending due to strong reactions to earnings, which included a beat and increased guidance, fueling bullish sentiment. The community highlights the company's exposure to the growing data center market and some are comparing its potential to that of $NVDA. Discussions also include possible price targets, long-term growth prospects, and the impact of technical factors.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

BIDU is trending as investors discuss its AI potential, particularly the expansion of its robotaxi service and recent Cathie Wood purchases. Community members are weighing positive catalysts against bearish sentiment and potential profit-taking. Broader discussions involve comparing valuations and growth prospects within the Chinese tech sector.

BlackRock Institutional Trust Company N.A. - iShares MSCI Japan ETF

iShares MSCI Japan ETF

EWJ is trending amid discussions of potential shifts in Japanese monetary policy and its impact on the yen. Community members are weighing the ETF's potential amid global economic uncertainty, with some noting technical breakout patterns. Broader market factors, such as inflation and central bank decisions in Japan, are also driving interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Leerink lowered its price target on Rocket Pharmaceuticals (RCKT) to $7 from $9 on Friday, following the company's announcement that it has voluntarily withdrawn its application for the approval of Fanskya to the U.S. Food and Drug Administration for the treatment of Fanconi Anemia.The analyst kept a ‘Market Perform’ rating on the shares, according to TheFly. The new price target, however, implies a potential upside of approximately 118% from the stock’s closing price on Thursday.Rocket Pharma <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001281895/000114036125037163/ef20056613_8k.htm">stated</a> in a filing with the Securities and Exchange Commission that the decision to withdraw the application for the gene therapy follows its decision to focus its resources on programs with the clearest regulatory and commercial pathways. The decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya or RP-L102, the company said.“Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable,” it added.The company ceased internal investment in Fanskya in July 2025 and withdrew its application with the European Medicines Agency (EMA) as part of a pipeline prioritization and corporate reorganization plan. The company had then warned that FDA approval of Fanskya is no longer expected in 2026.The therapy was tested in the treatment of Fanconi Anemia, a rare, inherited disorder characterized by a failure of the bone marrow to produce enough blood cells, leading to symptoms like fatigue, bleeding, and infections, as well as physical abnormalities and a significantly increased risk of certain cancers. &nbsp;The company said on Friday that it will consider external partnership opportunities to advance Fanskya in the future. “Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program,” it said.<a href="https://stocktwits.com/symbol/RCKT">Shares of RCKT</a> fell 2% at the time of writing. On Stocktwits, retail sentiment around RCKT remained within the ‘bearish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_57_15_PM_png_0ff4527f20.webp" alt="RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure> In August, Rocket Pharma <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> that the FDA had lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.RCKT stock is down by 75% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-to-schizophrenia-drug/chCuoM8R3QK">Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sculpture depicting a DNA strand in front of the Lawrence Hall of Science at UC Berkeley on Saturday, March 31, 2018. (Photo By Paul Chinn/The San Francisco Chronicle via Getty Images)

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 

Equity

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 


RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.The hold, <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">imposed</a> roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold">said</a>. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.Rocket Pharma stock shot up 25% in Wednesday’s pre-market session following the development. On Stocktwits, retail sentiment around RCKT rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels.&nbsp;Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.Following the death of a patient, Rocket paused further dosing in the mid-stage study, and on May 23, the FDA placed a clinical hold on the trial to allow for further evaluation. The trial can now resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing, followed by additional patients to complete the trial. The low dose has been determined as most likely to confer the safety and efficacy identified in the low-dose early-stage study cohorts, the company said.Rocket also said that it will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting the one administered in the early-stage study pediatric cohort. Further updates about the mid-stage study can be expected following review of data from the next three patients, the company said.RCKT stock is down by 77% this year and by about 85% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rocket Pharma Stock Up 25% Pre-Market Today? 

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

RCKT Stock Tanks on Patient Death in Danon Disease Study

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Rocket Pharmaceuticals Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$3.94
Prev Close	$3.85
Open	$3.90
Dividend Yield	0.00%
50-Day Moving Average	$3.42
Beta	1.21
Avg. Volume	2.07M
PE Ratio	-1.57

52-Week High	$18.17
52-Week Low	$2.19
Market Capitalization	$425.14M
EPS (Annual)	-$2.73
Price to Book	1.20
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCKT News

RCKTRocket Pharmaceuticals Inc